Ajanta Pharma gets USFDA nod for Parkinsons disease tablet
New Delhi: Ajanta Pharma has received final approval from the US health regulator for Entacapone tablets, used in the treatment of Parkinson's disease.
In a BSE filing, Ajanta Pharma said it has received "final approval for Entacapone tablets from US FDA. It is a bioequivalent generic version of Comtan tablets".
The company said it will launch the product shortly in the strength of 200mg tablets.
This new approval is part of the portfolio of products that the company has developed for the US market, it added.
Ajanta Pharma has 35 abbreviated new drug applications (ANDAs) of which it has final approval for 20 ANDAs, tentative approval for 2 ANDA and 13 ANDAs are under review with USFDA, Ajanta Pharma said.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd